Verity Asset Management Inc. lifted its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 20.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,626 shares of the biopharmaceutical company’s stock after purchasing an additional 454 shares during the quarter. Verity Asset Management Inc.’s holdings in Alexion Pharmaceuticals were worth $313,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Gradient Investments LLC raised its position in Alexion Pharmaceuticals by 30.7% during the fourth quarter. Gradient Investments LLC now owns 3,365 shares of the biopharmaceutical company’s stock valued at $402,000 after acquiring an additional 791 shares in the last quarter. Oppenheimer & Co. Inc. raised its position in Alexion Pharmaceuticals by 28.3% during the fourth quarter. Oppenheimer & Co. Inc. now owns 5,854 shares of the biopharmaceutical company’s stock valued at $700,000 after acquiring an additional 1,293 shares in the last quarter. California Public Employees Retirement System raised its position in Alexion Pharmaceuticals by 19.5% during the fourth quarter. California Public Employees Retirement System now owns 554,042 shares of the biopharmaceutical company’s stock valued at $66,258,000 after acquiring an additional 90,463 shares in the last quarter. Icon Advisers Inc. Co. raised its position in Alexion Pharmaceuticals by 7.1% during the fourth quarter. Icon Advisers Inc. Co. now owns 36,400 shares of the biopharmaceutical company’s stock valued at $4,353,000 after acquiring an additional 2,400 shares in the last quarter. Finally, ING Groep NV raised its position in Alexion Pharmaceuticals by 6.9% during the fourth quarter. ING Groep NV now owns 53,327 shares of the biopharmaceutical company’s stock valued at $6,377,000 after acquiring an additional 3,445 shares in the last quarter. Hedge funds and other institutional investors own 94.01% of the company’s stock.

In related news, CEO Ludwig Hantson sold 2,553 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $121.63, for a total transaction of $310,521.39. Following the transaction, the chief executive officer now owns 36,172 shares in the company, valued at $4,399,600.36. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Heidi L. Wagner sold 655 shares of Alexion Pharmaceuticals stock in a transaction on Monday, February 5th. The shares were sold at an average price of $117.26, for a total value of $76,805.30. Following the completion of the sale, the senior vice president now owns 32,635 shares in the company, valued at approximately $3,826,780.10. The disclosure for this sale can be found here. In the last quarter, insiders have sold 28,930 shares of company stock worth $3,378,199. 4.35% of the stock is currently owned by company insiders.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at $108.60 on Monday. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.10 and a quick ratio of 2.62. The stock has a market capitalization of $24,260.00, a P/E ratio of 55.13, a PEG ratio of 0.95 and a beta of 1.16. Alexion Pharmaceuticals, Inc. has a 12 month low of $96.18 and a 12 month high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.09 by $0.39. The firm had revenue of $909.70 million for the quarter, compared to analyst estimates of $880.38 million. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. The business’s revenue was up 9.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.26 earnings per share. research analysts predict that Alexion Pharmaceuticals, Inc. will post 6.25 EPS for the current fiscal year.

ALXN has been the subject of several recent research reports. Zacks Investment Research cut Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, November 1st. TheStreet cut Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Friday, November 10th. Robert W. Baird upgraded Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $150.00 price target for the company in a research report on Monday, December 18th. Royal Bank of Canada lifted their price target on Alexion Pharmaceuticals to $166.00 in a research report on Tuesday, October 24th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $170.00 price target on shares of Alexion Pharmaceuticals in a research report on Monday, October 23rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and twenty-one have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $153.14.

ILLEGAL ACTIVITY NOTICE: “Alexion Pharmaceuticals, Inc. (ALXN) Shares Bought by Verity Asset Management Inc.” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://theolympiareport.com/2018/02/12/alexion-pharmaceuticals-inc-alxn-shares-bought-by-verity-asset-management-inc.html.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.